Dr. Marshall said that the market for cancer drugs is changing rapidly. "We have a shifting model from where everybody with breast cancer is going to get Taxol, to certain patients are going to get certain medicines," he said, adding that this shrinks the overall market for a product and thus, probably the interest in investing in that therapy.